Rapport Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Rapport Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $269.44M.
- Rapport Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $140.87M.
- Rapport Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2025 was $269.44M, a 91.27% increase from fiscal 2024.
- Rapport Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2024 was $140.87M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $269.44M 10-K · filed 2026-03-10 | |
| 2025-09-30 | $269.44M 10-Q · filed 2025-11-06 | |
| 2024-12-31 | $140.87M 10-K · filed 2026-03-10 | |
| 2024-06-30 | $140.87M 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |